Role of APOA1 in the resistance to platinum-based chemotherapy in squamous cervical cancer

To investigate the mechanism by which apolipoprotein A1 (APOA1) enhances the resistance of cervical squamous carcinoma to platinum-based chemotherapy. Two cervical squamous carcinoma cell lines (SiHa and Caski) overexpressing APOA1 were constructed, treated with carboplatin, and compared to normal c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC cancer 2022-04, Vol.22 (1), p.411-411, Article 411
Hauptverfasser:	He, Yue, Han, Su-Bin, Liu, Yang, Zhang, Jing-Jing, Wu, Yu-Mei
Format:	Artikel
Sprache:	eng
Schlagworte:	1-Phosphatidylinositol 3-kinase Analysis Apolipoprotein A-I - genetics Apolipoprotein A1 Apolipoproteins Breast Neoplasms Cancer Cancer therapies Carboplatin Carcinoma, Squamous Cell - drug therapy Care and treatment CD81 antigen Cervical cancer Cervix Chemoresistance Chemotherapy Chemotherapy resistance Chromatography Cloning Diagnosis Female Genomes Humans Localization MAP kinase Patient outcomes Peptides Phosphatidylinositol 3-Kinases Platinum Platinum - therapeutic use Platinum,Proteomics Proteins Proteomics Risk factors Signal transduction Stat1 protein Tumor cell lines Tumors Uterine Cervical Neoplasms - drug therapy Uterine Cervical Neoplasms - genetics Uterine Cervical Neoplasms - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To investigate the mechanism by which apolipoprotein A1 (APOA1) enhances the resistance of cervical squamous carcinoma to platinum-based chemotherapy. Two cervical squamous carcinoma cell lines (SiHa and Caski) overexpressing APOA1 were constructed, treated with carboplatin, and compared to normal control cells. In both SiHa and Caski cell lines, the clone-forming ability of CBP-treated cells was lower than that of untreated cells, and the change in the number of clones of overexpressing cells was lower than that of normal control cells (p
ISSN:	1471-2407 1471-2407
DOI:	10.1186/s12885-022-09528-x